SCM
MDNA

Soleus Capital Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Soleus Capital Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-186,799
Closed -$874K – 86
2020
Q4 		$874K Sell
186,799
-62,061
-25% -$250K 0.12% 56
2020
Q3 		$1.03M Buy
+248,860
New +$1M 0.55% 43

Other funds holding MDNA

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Soleus Capital Management's MDNA Position: Q1 2021 in Review

Soleus Capital Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q1 2021, closing a stake of 186,799 shares — an estimated $874K sold.

Soleus Capital Management first reported a position in MDNA in Q3 2020 and held it in 2 quarters. The position peaked at $1.03M in Q3 2020. 31 funds tracked by Wall St. Rank hold MDNA as of Q1 2021.

  • Soleus Capital Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q1 2021 after selling out during the quarter.
  • Soleus Capital Management sold 186,799 Medicenna Therapeutics Corp. Common Shares shares in Q1 2021, an estimated $874K.
  • Soleus Capital Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 2 quarters.
  • Soleus Capital Management's Medicenna Therapeutics Corp. Common Shares position peaked at $1.03M in Q3 2020.
  • 31 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q1 2021.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.